455,380 Shares in Xeris Biopharma Holdings, Inc. $XERS Acquired by Man Group plc

Man Group plc bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 455,380 shares of the company’s stock, valued at approximately $3,607,000.

Several other institutional investors have also added to or reduced their stakes in XERS. Walleye Capital LLC purchased a new position in Xeris Biopharma in the 2nd quarter worth about $4,841,000. Rice Hall James & Associates LLC purchased a new stake in shares of Xeris Biopharma during the 1st quarter valued at about $1,456,000. Janus Henderson Group PLC grew its stake in shares of Xeris Biopharma by 322.8% in the first quarter. Janus Henderson Group PLC now owns 295,489 shares of the company’s stock worth $1,713,000 after acquiring an additional 225,602 shares during the period. Granahan Investment Management LLC grew its stake in shares of Xeris Biopharma by 249.4% in the fourth quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock worth $9,604,000 after acquiring an additional 873,236 shares during the period. Finally, Emerald Mutual Fund Advisers Trust purchased a new position in shares of Xeris Biopharma during the first quarter valued at approximately $1,204,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Stock Down 0.5%

XERS opened at $8.44 on Tuesday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $10.08. The company has a market capitalization of $1.54 billion, a PE ratio of -76.73 and a beta of 0.66. The firm’s 50 day simple moving average is $8.32 and its two-hundred day simple moving average is $6.93.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million. Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. As a group, equities analysts forecast that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00. Following the transaction, the insider directly owned 1,361,053 shares of the company’s stock, valued at $11,568,950.50. The trade was a 0.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $8.02, for a total value of $120,300.00. Following the transaction, the insider owned 1,676,126 shares of the company’s stock, valued at approximately $13,442,530.52. This trade represents a 0.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 254,832 shares of company stock valued at $1,937,915 in the last ninety days. 4.35% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Barclays increased their target price on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.